Pembrolizumab for Inflammatory Breast Neoplasms
This study is evaluating whether a drug may help treat inflammatory breast cancer or triple negative breast cancer.
See full descriptionAbout the trial for Inflammatory Breast Neoplasms
Treatment Groups
This trial involves 2 different treatments. Pembrolizumab is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 2 and have already been tested with other people.
About The Treatment
Eligibility
This trial is for patients born any sex aged 18 and older. You must have received 1 prior treatment for Inflammatory Breast Neoplasms or one of the other 12 conditions listed above. There are 10 eligibility criteria to participate in this trial as listed below.
Approximate Timelines
Measurement Requirements
This trial is evaluating whether Pembrolizumab will improve 1 primary outcome and 3 secondary outcomes in patients with Inflammatory Breast Neoplasms. Measurement will happen over the course of Baseline.
Patient Q & A Section
What are the signs of inflammatory breast neoplasms?
Inflammatory breast neoplasms usually appear as a mass on the breast. They may become painful and red, as well as itch and feel warm to the touch. Symptoms of breast infections are common and usually occur with palpable masses or with a lump on the breast. In addition, some patients experience erythema, edema or tenderness, but other signs and symptoms may not appear until the tumour has progressed. In the final stages of breast cancer, the breast will usually feel lumpy, hot, swollen or hard. As the tumour continues to grow, there may be a lump or nodule on the nipple that is painless or tender. Lymph nodes can be painful and may feel swollen or heavy.
What is inflammatory breast neoplasms?
Inflammatory breast neoplasms occur in 1 out of 1000 to 3000 breast biopsies and involve the tissue between the basement membrane and the underlying connective tissue supporting the epithelium. There are different subtypes according to the pathological pattern of the tumor mass and the localization of the tumor. Clinically, the subtypes include low grade carcinoma with apocrine differentiation, intermediate and high grade carcinoma with spindle cell pattern and the carcinoma in situ. They might have a better prognosis if managed according to the type.
What causes inflammatory breast neoplasms?
IBNs might be caused by a low levels of androgens, estrogens, and progesterone and/or low levels of growth factor. The low levels of progesterone and estrogen might come from the low levels of androgen and the low levels of growth factor. The low levels of testosterone level could be one of the causes. There are also some genes (such as BRCA1, ERBB3, and STAT-3) associated with IBNs, and these genes are related to estrogen.
Can inflammatory breast neoplasms be cured?
Results from a recent paper suggests that IBN may be curable but that the rate of healing may be influenced by the histological type and by patient age.
What are common treatments for inflammatory breast neoplasms?
Different treatment regimens exist for breast cancer associated with inflammatory conditions such as systemic mastocytosis or Behçet's disease. Treatment with chemotherapy followed by surgical resection is appropriate for symptomatic cases. Surgery is the gold standard for curative treatment in most cases, especially in localized disease.
How many people get inflammatory breast neoplasms a year in the United States?
About 10 million women in the United States and Canada have a history of breast cancer; nearly 8 million of these cases are due to in-viromeous conditions. IBC accounted for approximately 1% of breast cancers in the United States in 2008. The age-adjusted incidence rate of IBC in the United States was 3.8 per 100,000 women, and it was much higher in black women (13.5 per 100,000) than in white women (2.9 per 100,000). The age-adjusted rate of IBC incidence increased from 3,828 cases in 1992 to 16,531 cases in 1994, and 24,913 cases in 1998.
Does inflammatory breast neoplasms run in families?
Data from a recent study of this study suggest that there are no genetic risk factors predisposing IBN patients and families to develop IBN. A genetic basis for familial susceptibility to IBN is not supported by the results of this investigation.
What are the common side effects of pembrolizumab?
The common adverse drug reactions associated with pembrolizumab are summarized below.\n\n- Hypothyroidism: hypothyroidism is the most common side effect observed with pembrolizumab treatment. The usual clinical signs and symptoms of hypothyroidism are reproduced in the table below.\n- Elevated liver enzymes: Elevated liver enzymes are the most frequent serum enzyme rises observed during the treatment with pembrolizumab. If any of the elevations is significant you could visit, www.powerlab.com: http://www.powerlab.
What is the latest research for inflammatory breast neoplasms?
For the most part, recent research has been geared toward improving our understanding of the molecular basis of the disease, to improving our knowledge of the etiology and progression of the disease, and to improving therapies. For those interested in future research and treatment options for IBN, we recommend using Power (https://www.withpower.com/d/cancer-research) to find clinical trial options tailored to your medical condition and location.
What is pembrolizumab?
Pembrolizumab was well tolerated in this phase II study of metastatic breast cancer patients with a variety of histologic subtypes. Long-term results of the study will be published in 2020. Pembrolizumab did not result in a change in prognosis in either responders or remitters after 6 weeks of therapy. Data from a recent study are not expected to change the current clinical practice of administering pembrolizumab in patients with metastatic breast cancer patients with hormone receptor-positive and/or HER2/neu overexpressing tumors who are hormone receptor positive, HER2/neu positive, or either in patients who have an orphan, or BRCA1/BRCA2 mutation.
What are the chances of developing inflammatory breast neoplasms?
It is estimated that in the general USA population, the chances of developing IBNs in a woman are 1.2 in 2000, and the chances of IBNs progressing to Invasiveness is 1.2 in 2500.
What is the primary cause of inflammatory breast neoplasms?
There is ample biological evidence to support a viral-induced proliferative cascade in the pathogenesis of invasive breast lesions. This concept provides an explanation for the high prevalence of non-neoplastic breast lesions in association with invasive breast cancer and emphasizes the importance of the biologic properties of the neoplastic cascade to its pathogenesis.